Clinical trial · Interventional
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated). Following recovery, patients will receive a medication called Brentuximab Vendotin which is targeted against CD30+ cells. The study hypothesis is that this treatment will be safe and well tolerated in children and young adults.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Allogeneic Stem Cell Transplantation | Procedure | — | UNRESOLVED |
| Brentuximab Vedotin | Drug | Brentuximab Vedotin | ALIAS |
| Reduced Intensity Conditioning | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Allogeneic Transplant and Immunotherapy
- description
- We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
- interventionNames
- Drug: Brentuximab Vedotin
- Procedure: Allogeneic Stem Cell Transplantation
- Drug: Reduced Intensity Conditioning
Primary outcomes (2)
- measure
- Safety
- timeFrame
- 1 year
- description
- Patients will be followed for one year for adverse events related to the administration of study drug.
- measure
- Overall Survival
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * 45 years of age or less. * Patients with Hodgkin Lymphoma with either of the following: • Primary induction failure (failure to achieve initial CR) and/or primary refractory disease OR First, Second or Third relapse AND History of prior ablative auto HSCT or ineligible for an ablative auto HSCT or ≥25% residual disease after at least two reinduction chemotherapy cycles AND HLA matched family donor (6/6 or 5/6) or matched unrelated adult donor (MUD) (8/8) or matched umbilical cord blood unit (≥5/6) with prethaw cell dose of at least 3 x 107/kg TNC. * off other investigational therapy for one month prior to entry in this study. * adequate organ function Exclusion Criteria: * Patients with HD with 4th or greater CR, PR, and/or SD are ineligible. * Patients with rapidly progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy are ineligible. * Patients who don't have an eligible donor are ineligible. * Women who are pregnant are ineligible.
References
Publications (0)
Data not yet available